Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, up to 36 Months in Patients with Active Psoriatic Arthritis: Data from the Third Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study
- Publication date
- 1 September 2018
- Publisher
- 'Royal College of Obstetricians & Gynaecologists (RCOG)'